首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1458102

全球幹細胞治療市場規模、佔有率、成長分析，依治療（自體和同種異體）、依應用（再生醫學、藥物發現和開發）- 2024-2031 年行業預測

Global Stem Cell Therapy Market Size, Share, Growth Analysis, By Therapy(Autologous, and Allogenic), By Application(Regenerative Medicine, Drug Discovery and Development) - Industry Forecast 2024-2031

出版日期: 2024年03月25日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球幹細胞治療市場規模為121.1億美元，預計將從2023年的133.3億美元成長到2031年的287.9億美元，預測期間（2024-2031年）複合年成長率為10.1%。

幹細胞治療產業的主要目標是為各種疾病提供尖端的解決方案。幹細胞療法的目標是治療目前很少或沒有有效替代療法的疾病和損傷。該市場旨在利用幹細胞的再生特性，為患有心血管疾病、神經系統疾病、骨科損傷、自體免疫疾病和某些癌症等疾病的患者帶來希望。全球幹細胞治療市場的擴張。與年齡相關的疾病和慢性疾病的發生率上升是主要原因之一。

幹細胞治療的高價格是主要障礙之一。幹細胞治療市場面臨許多障礙。監管和標準化的要求是主要障礙之一。隨著這些治療的進展，為幹細胞療法的開發、製造和臨床應用建立精確的規範和標準變得越來越重要。成本效益和可擴展性是市場面臨的兩個問題。仍需要克服的一個主要障礙是增加幹細胞療法的產量以滿足需求，同時保持品質和成本下降。儘管有困難，幹細胞治療市場仍呈現出巨大的潛力。越來越多的臨床試驗和研究調查幹細胞療法的潛力，預示著光明的未來。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

Novartis AG (Switzerland)
Pfizer Inc. (US)
Mesoblast Limited (Australia)
Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)
TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)
Gamida Cell Ltd. (Israel)
Vericel Corporation (US)
Medipost Co., Ltd. (South Korea)
Astellas Pharma Inc. (Japan)
Osiris Therapeutics, Inc. (US)
NuVasive, Inc. (US)
Cynata Therapeutics Limited (Australia)
Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)
Lonza Group Ltd. (Switzerland)
Caladrius Biosciences, Inc. (US)
Athersys, Inc. (US)
Cytori Therapeutics, Inc. (US)
Holostem Terapie Avanzate Srl (Italy)
Pluristem Therapeutics Inc. (Israel)
BioTime, Inc. (US)

簡介目錄

Product Code: SQMIG35H2162

Global Stem cell therapy Market size was valued at USD 12.11 Billion in 2022 and is poised to grow from USD 13.33 Billion in 2023 to USD 28.79 Billion by 2031, at a CAGR of 10.1% during the forecast period (2024-2031).

The main goal of the stem cell therapy industry is to offer cutting-edge solutions for a variety of illnesses. The goal of stem cell therapies is to treat illnesses and injuries for which there are currently few or no effective therapy alternatives. This market aims to give patients with ailments like cardiovascular diseases, neurological disorders, orthopedic injuries, autoimmune diseases, and some kinds of cancer hope by utilizing the regenerative characteristics of stem cells. the expansion of the market for stem cell therapy worldwide. The rising incidence of age-related illnesses and chronic disorders is one of the main causes.

The high price of stem cell treatments is one of the main obstacles. Numerous obstacles confront the market for stem cell therapy. The requirement for regulation and standardization is one of the main obstacles. Establishing precise norms and standards for stem cell therapy development, manufacturing, and clinical application is becoming more and more important as these treatments progress. Cost-effectiveness and scalability are two issues the market is facing. One major obstacle that still needs to be overcome is increasing the production of stem cell therapies to satisfy demand while keeping quality and costs down. Despite the difficulties, the market for stem cell therapy presents a lot of potential. A bright future is suggested by the growing number of clinical trials and research investigations examining the potential of stem cell therapy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Stem Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Stem Cell Therapy Market Segmental Analysis

The therapy, application, and geographic segments of the worldwide stem cell therapy market are divided up. The market is divided into two categories for therapy: autologous and allogeneic. The market is divided into three categories based on application: drug development, regenerative medicine, and discovery. The market is divided into Latin America, Middle East and Africa, Asia Pacific, North America, and Europe.

Drivers of the Global Stem Cell Therapy Market

One major factor propelling the stem cell therapy market is the increasing prevalence of chronic diseases like neurological illnesses, orthopedic injuries, and cardiovascular ailments. With the ability to repair damaged tissues and organs, stem cell therapies offer patients new therapy options when there are few or no other viable options.

Restraints in the Global Stem Cell Therapy Market

One major obstacle to the broad acceptance of stem cell therapies is their high cost. The cost of these treatments is considerable due in part to the complexity of manufacturing, research and development activities, and regulatory restrictions. This restricts many patients' access to stem cell treatments, especially in areas with lower incomes.

Market Trends of the Global Stem Cell Therapy Market

A greater emphasis is being placed on allogeneic therapies: these treatments, which employ donor cells, have become more popular. Benefits of this technique include lower production costs, uniform and easily accessible cell sources, and maybe off-the-shelf therapies. There is a growing pipeline of clinical trials and product development in the field of allogeneic cell therapy as a result of numerous companies refocusing their efforts on this area.

Personalized Medicine and Cell Banking: The field of personalized medicine, which involves customizing treatment plans for each patient according to their specific traits, is becoming more and more popular in the stem cell therapy industry. The process of collecting and preserving human cells for potential therapeutic applications, known as cell banking, is gaining significance. This strategy makes it possible to provide prompt, individualized treatment alternatives, especially in autologous therapies, which use the patient's own cells.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Stem Cell Therapy Market by Therapy

Market Overview
Autologous
and Allogenic

Global Stem Cell Therapy Market by Application

Market Overview
Regenerative Medicine
Drug Discovery and Development

Global Stem Cell Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gamida Cell Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medipost Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Osiris Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NuVasive, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cynata Therapeutics Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caladrius Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytori Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Holostem Terapie Avanzate S.r.l. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pluristem Therapeutics Inc. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioTime, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments